Pour savoir comment effectuer et gérer un dépôt de document, consultez le « Guide abrégé – Dépôt de documents » sur le site Web de la Bibliothèque. Pour toute question, écrivez à corpus@ulaval.ca.
 

Publication :
A pharmacogenetics study of the human glucuronosyltransferase UGT1A4

bul.description.provenanceemofr_CA
bul.description.provenancespbfr_CA
bul.rights.dateAccepPubl2009-12-01fr_CA
bul.rights.periodeEmbargoP1Yfr_CA
bul.rights.typeDatedatePublicationfr_CA
dc.audiencePharmaciensfr_CA
dc.audienceProfesseurs (Enseignement supérieur)fr_CA
dc.audienceÉtudiantsfr_CA
dc.audienceDoctorantsfr_CA
dc.contributor.authorBenoît-Biancamano, Marie-Odile
dc.contributor.authorLeblanc, Marie-Hélène
dc.contributor.authorBernard, Olivier
dc.contributor.authorCourt, Michael H.
dc.contributor.authorGuillemette, Chantal
dc.contributor.authorCaron, Patrick
dc.contributor.authorAdam, Jean-Philippe
dc.date.accessioned2016-09-30T13:20:15Z
dc.date.available2016-09-30T13:20:15Z
dc.date.issued2009-12-01
dc.description.abstractUGT1A4 is primarily expressed in the liver and exhibits catalytic activities for various drugs. Amongst the few UGT1A4 polymorphisms evaluated, studies support the alteration of UGT1A4-mediated glucuronidation by a few variations including the Pro24Thr and Leu48Val variants (referred to as UGT1A4*2 and *3). We therefore investigated genetic mechanisms that might contribute to interindividual variation in UGT1A4 expression and activity. The UGT1A4 gene was sequenced from -4963 bp relative to the ATG to 2000 bp after the first exon in 184 unrelated Caucasians and African-Americans. We identified a large number of genetic variations, including 13 intronic, 39 promoter, as well as 14 exonic polymorphisms, with 10 that lead to aminoacid changes. Of the nucleotide variations found in the -5kb promoter region, 5 are located in the proximal region (first 500 bp), and positioned in putative HNF-1 and OCT-1 binding sites. Four of these variants, placed at -163, -219, -419 and -463, are in complete linkage disequilibrium with the Leu48Val coding region variant and with several variants in the upstream region of the promoter. Transient transfections of reference and variant promoter constructs (from position -500 to +1) in different cell lines with or without co-expression of HNF-1 and/or OCT-1, demonstrated limited effect of these variations. However, several coding variants significantly modified the enzyme kinetics for tamoxifen and Z-4-hydroxytamoxifen (Val48, Asp50, Gln56, Phe176, Asn250, Leu276). Our results reveal that, despite a large number of polymorphisms located in the promoter region, the exonic variants are those expected to have a potential in vivo effect.fr_CA
dc.identifier.doi10.1097/FPC.0b013e3283331637fr_CA
dc.identifier.issn1744-6872fr_CA
dc.identifier.pubmed19890225fr_CA
dc.identifier.urihttp://hdl.handle.net/20.500.11794/10669
dc.languageengfr_CA
dc.publisherLippincott Williams & Wilkinsfr_CA
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.subjectPharmacogeneticsfr_CA
dc.subjectPolymorphismsfr_CA
dc.subjectTamoxifenfr_CA
dc.subjectUGTfr_CA
dc.subject.rvmGlucuronosyltransférasefr_CA
dc.subject.rvmPharmacogénétiquefr_CA
dc.subject.rvmPolymorphisme génétiquefr_CA
dc.subject.rvmTamoxifènefr_CA
dc.titleA pharmacogenetics study of the human glucuronosyltransferase UGT1A4fr_CA
dc.typearticle de recherche
dc.type.legacyCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherche
dcterms.bibliographicCitationPharmacogenetics and genomics, Vol. 19 (12), 945–954 (2009)fr_CA
dspace.accessstatus.time2024-03-25 18:12:11
dspace.entity.typePublication
relation.isAuthorOfPublication7b1734e6-ab37-4db3-a395-ba73c099fd82
relation.isAuthorOfPublication8e83bec6-0490-4e2a-9e2d-e6bcad75c1db
relation.isAuthorOfPublicationb10210c0-d867-4e51-afb6-2c23082b8cee
relation.isAuthorOfPublicationbca1530c-d609-4030-a208-19451a4c1ce0
relation.isAuthorOfPublicationc147729e-5c6d-4f3a-acd6-4b3a8e04bee9
relation.isAuthorOfPublicationf8c3065b-6be1-4ff7-b342-13bfd775b060
relation.isAuthorOfPublication.latestForDiscovery7b1734e6-ab37-4db3-a395-ba73c099fd82
relation.isResourceTypeOfPublication4c433ef5-3937-4530-8252-cca17d715747
relation.isResourceTypeOfPublication.latestForDiscovery4c433ef5-3937-4530-8252-cca17d715747
rioxxterms.projectMOP-42392fr_CA
rioxxterms.project.funder-nameCanadian Institutes of Health Researchfr_CA
rioxxterms.versionAccepted Manuscript (AM)fr_CA
rioxxterms.version-of-recordhttps://doi.org/10.1097/FPC.0b013e3283331637fr_CA

Fichiers

Bundle original
Voici les éléments 1 - 1 sur 1
En cours de chargement...
Vignette d'image
Nom :
UGT1A4 PGx 12-06-2009.pdf
Taille :
612.63 KB
Format :
Adobe Portable Document Format